BRIEF-Merck & Co Inc Says FDA Sets PDUFA Date Of June 19, 2026 For Welireg And Keytruda

Merck & Co., Inc.

Merck & Co., Inc.

MRK

0.00

Feb 28 (Reuters) - Merck & Co Inc MRK.N:

  • KEYTRUDA® (PEMBROLIZUMAB) PLUS WELIREG® (BELZUTIFAN) GIVEN AS ADJUVANT THERAPY REDUCED THE RISK OF DISEASE RECURRENCE OR DEATH BY 28% COMPARED TO KEYTRUDA MONOTHERAPY IN CERTAIN PATIENTS WITH EARLIER-STAGE RENAL CELL CARCINOMA (RCC)

  • MERCK & CO INC - KEYTRUDA PLUS WELIREG REDUCES RISK OF RECURRENCE OR DEATH BY 28%

  • MERCK & CO INC - FDA ACCEPTS PRIORITY REVIEW FOR WELIREG AND KEYTRUDA COMBINATION

  • MERCK & CO INC - FDA SETS PDUFA DATE OF JUNE 19, 2026 FOR WELIREG AND KEYTRUDA

Source text: ID:nBw7Rg3KLa

Further company coverage: MRK.N


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.